CYP19A1 and breast cancer: It is plausible that various factors are associated with the increased risk observed among AI users, such as the dose of vaginal estrogen, the dosage of aromatase inhibitors, or even the temporal relationship between the initiation of VET and the breast cancer diagnosis.(13)